Author + information
- Received September 9, 2017
- Revision received November 6, 2017
- Accepted November 15, 2017
- Published online January 15, 2018.
- W. Schuyler Jones, MD and
- Manesh R. Patel, MD∗ ()
- Department Heart Center and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
- ↵∗Address for correspondence:
Dr. Manesh R. Patel, Duke University Medical Center, Box 3330, Durham, North Carolina 27710.
Atherosclerotic cardiovascular (CV) disease remains a major health concern affecting more than 200 million adults worldwide, and lower extremity peripheral artery disease (PAD) is associated with significant morbidity and mortality. Treatment strategies to reduce the burden of major adverse CV events and limb events have mainly involved the use of antiplatelet and statin medications. Unlike other types of atherosclerotic CV disease, the evidence base is not well developed for therapies in patients with PAD. Recently, studies from subgroups of patients with PAD and a large clinical trial of PAD patients have been published, signaling a burgeoning interest in studying this higher risk population. This review outlines the inherent CV risks of patients with PAD, risk reduction strategies, emerging clinical trial data, and opportunities for the CV community to generate evidence in real-world settings and translate evidence into practice as new therapies become available.
Dr. Jones has received research grants from the Agency for Healthcare Research and Quality, AstraZeneca, American Heart Association, Bristol-Myers Squibb, the Doris Duke Charitable Foundation, Merck, and the Patient-Centered Outcomes Research Institute; and has received honorarium/other from the American College of Physicians, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, and Janssen Pharmaceuticals. Dr. Patel has received research grants from AstraZeneca, Bayer, National Heart, Lung, and Blood Institute, and Heartflow; and has received honorarium/other from Medscape, Bayer, Janssen Pharmaceuticals, and AstraZeneca.
- Received September 9, 2017.
- Revision received November 6, 2017.
- Accepted November 15, 2017.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.